Earnings Call Summary | ProSomnus(OSA.US) Q4 2023 Earnings Conference
Earnings Call Summary | ProSomnus(OSA.US) Q4 2023 Earnings Conference
The following is a summary of the ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript:
以下是ProSomnus, Inc.（OSA）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
ProSomnus reported a record revenue for Q4 2023 of $7.8 million and a full-year 2023 revenue of $27.7 million.
The company has seen eight consecutive quarters of sequential revenue growth, with Q4 2023 revenue growth at 35% and full-year 2023 at 43%.
Operating expenses for Q4 2023 were $12.8 million, showing an improvement on a percent revenue basis.
ProsomNus報告稱，2023年第四季度收入創歷史新高，爲780萬美元，2023年全年收入爲2770萬美元。
該公司已連續八個季度實現收入連續增長，2023年第四季度收入增長35％，2023年全年收入增長43％。
2023年第四季度的運營支出爲1,280萬美元，按收入百分比計算有所改善。
Business Progress:
業務進展：
ProSomnus positioned itself as the leading non-CPAP obstructive sleep apnea (OSA) therapy based on several factors such as device demand and access to care.
They demonstrated technical feasibility of their next-generation RPMO2 with positive data from a pilot study.
ProSomnus is currently working through the FDA process for the ProSomnus EVO device and plans to apply for FDA clearance later this year.
The company expects that ProSomnus RPMO2 device will impact sleep medicine by improving disease management and reducing care costs.
Continuous recalls of Philips Respironics' CPAP devices are expected to create more opportunities for non-CPAP therapies offered by ProSomnus.
基於設備需求和獲得醫療服務的機會等多種因素，Prosomnus將自己定位爲領先的非CPAP阻塞性睡眠呼吸暫停（OSA）療法。
他們利用一項試點研究的積極數據證明了其下一代 RPMO2 的技術可行性。
Prosomnus目前正在研究Prosomnus EVO設備的美國食品藥品管理局程序，並計劃在今年晚些時候申請美國食品藥品管理局的許可。
該公司預計，ProsomNUS RPMO2 設備將通過改善疾病管理和降低醫療成本來影響睡眠醫學。
飛利浦呼吸公司的CPAP設備的持續召回預計將爲Prosomnus提供的非CPAP療法創造更多機會。
More details: ProSomnus IR
更多詳情： Prosomnus IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。